Suven Life to unveil new drug candidates at US neuroscience meet
12 November 2010
Suven Life Sciences will present data on several new chemical entities (NCEs) in its portfolio of investigational neuroscience at the Society for Neuroscience annual meeting (SFN 2010) in San Diego, US, from 13 to 19 November.
More than 30,000 neuro scientists from across the world covering major pharma, biotech and research institutes are expected to participate in `Neuroscience' - the annual meeting of the Society for Neuroscience.
Suven's data presentations will cover the early-stage compounds from Nicotinic acetylcholine alpha-4-beta-2 receptor agonist and antagonist, Histamine-3 receptor antagonist and Serotonin 5-HT4 receptor agonist in addition to 5HT6 antagonists to treat unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer's, Schizophrenia, ADHD; depression and mood disorders and meuropathic pain, Suven said in a release.
"These data presentations highlight Suven's commitment to exploring new treatment options that address unmet medical needs with a market size of more than $30 billion," the company said.
During SFN-2010 Suven had lined up several collaborative research programmes as also drug discovery and development support services in addition to continued discussions with global pharma majors for licensing and development of its clinical candidate SUVN-502.
Suven said its CNS drug discovery scientists at Hyderabad are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, schizophrenia, depression, cognitive disorders, sleep, neurodegeneration and obesity through CNS targets.
Suven is engage in discovery and development of several small molecules in pharma and biotech industry through collaborative research with Eli Lilly, AstraZeneca, BMS, Johnson & Johnson, Pfizer, Abbott, Eli Lilly, Lundbeck, Reviva, Theravance, Onconova and Kareus.